YD Bio Ltd. Announces Audit Committee Leadership Change
Ticker: YDESW · Form: 6-K · Filed: Nov 17, 2025 · CIK: 2011674
| Field | Detail |
|---|---|
| Company | Yd Bio Ltd (YDESW) |
| Form Type | 6-K |
| Filed Date | Nov 17, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 3 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: governance, board-change, audit-committee
TL;DR
YD Bio Ltd. board shakeup: Audit Committee Chair Joseph Tseng resigns, new chair appointed.
AI Summary
YD Bio Limited announced on October 27, 2025, the resignation of Joseph Hing Lung Tseng as an independent director and Chairman of the Audit Committee. The company has appointed a new Audit Committee Chair, though the name is not specified in this filing. This change affects the governance structure of YD Bio Limited.
Why It Matters
Changes in audit committee leadership can signal shifts in financial oversight and governance, potentially impacting investor confidence and regulatory compliance.
Risk Assessment
Risk Level: low — The filing reports a routine change in board leadership without any indication of financial distress or significant operational issues.
Key Players & Entities
- YD Bio Limited (company) — Registrant
- Joseph Hing Lung Tseng (person) — Resigning Director and Audit Committee Chair
- October 27, 2025 (date) — Date of resignation and appointment
FAQ
Who has been appointed as the new Audit Committee Chair?
The filing states that a new Audit Committee Chair has been appointed, but the name of the individual is not disclosed in this report.
When did Joseph Hing Lung Tseng's resignation take effect?
Joseph Hing Lung Tseng's resignation as an independent director and Chairman of the Audit Committee was accepted by the Board of Directors on October 27, 2025.
What was Joseph Hing Lung Tseng's role prior to his resignation?
Joseph Hing Lung Tseng was an independent director of the Board and the Chairman of the Audit Committee of YD Bio Limited.
What type of filing is this for YD Bio Limited?
This is a Form 6-K filing, which is a Report of Foreign Private Issuer pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934.
Where is YD Bio Limited's principal executive office located?
YD Bio Limited's principal executive offices are located at 12F., No. 3, Xingnan St., Nangang Dist., Taipei City 115001, Taiwan.
Filing Stats: 653 words · 3 min read · ~2 pages · Grade level 9.8 · Accepted 2025-11-17 17:25:01
Filing Documents
- ea0265957-6k_ydbio.htm (6-K) — 14KB
- 0001213900-25-111626.txt ( ) — 16KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. November 17, 2025 YD BIO LIMITED By: /s/ Edmund Hen Name: Edmund Hen Title: Chief Financial Officer 2